Evotec-RSIL Ltd Extends Library Synthesis Collaboration with Ferrer Grupo
News Jul 10, 2009
Evotec-RSIL Ltd. has announced that Ferrer Grupo, the Spanish pharmaceutical and healthcare company has extended their ongoing collaboration.
The two year extension is the third agreement between Ferrer Grupo and Evotec-RSIL in the last year and is based on the results achieved by Evotec-RSIL in generating libraries on schedule and to the agreed high quality standards.
Evotec-RSIL uses its skills and expertise in parallel synthesis and purification to deliver high quality, focused libraries that represent a major part of Ferrer Grupo's screening collection.
Lester Marrison, CSO of Evotec-RSIL Ltd. commented, "We are extremely pleased and proud that Ferrer Grupo has decided to extend our collaboration. During the last 2 years Evotec-RSIL has established itself as a partner of choice for an increasing number of pharmaceutical and biotechnology companies. Our work with Ferrer Grupo is a great example of our ability to consistently deliver high quality compound libraries, cost effectively and to agreed timelines".
Albert Palomer, Head of the Medicinal Chemistry Department of Ferrer Grupo commented, "Our collaboration with Evotec-RSIL is important for the establishment of a high quality screening library at Ferrer. During the past 12 months the partnership has been very productive and generated multiple, focused libraries ahead of our original timelines. Our experience with previous, successful collaborations with Evotec-RSIL meant that we had no hesitation in extending our agreement yet again".
Evotec-RSIL is a joint venture between Evotec AG the Indian CRO, Research Support International Ltd (RSIL Ltd). Through the joint venture, Evotec transferred resources, equipment and expertise to state-of-the-art laboratories in India in order to provide cost effective contract services for library synthesis.
The commitment to total flexibility, validated processes and a proven track record have contributed to the rapid expansion of the joint venture providing compound library synthesis services to major European and US pharmaceutical and biotechnology companies.
No financial details are disclosed.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE